The combination treatment with the PD-1 inhibitor sintilimab, anti-VEGF therapy, and chemotherapy demonstrated a significant improvement in PFS in a NSCLC patient who developed acquired resistance due to EGFR 19Del/T790M/cis-C797S mutation after progression on EGFR TKI therapy. Here, PDCD1 is linked to non-small cell lung carcinoma.